Our Company

It began with a promise. More than 100 years ago, CSL was formed to save lives using the latest technologies. In the century since, CSL Behring has grown into a global biotechnology leader, driven by that same promise to save and improve lives. We offer the broadest range of quality plasma-derived and recombinant therapies in our industry. Our ability to innovate and deliver life-saving medicines for patients with unmet medical needs around the world has earned us a reputation for always putting patients first. We are CSL Behring and we are driven by our promise.

CSL was established in Australia in 1916 to service the health needs of a nation isolated by war. Over the ensuing years CSL provided Australians with rapid access to 20th century medical advances including insulin and penicillin, and vaccines against influenza, polio and other infectious diseases. CSL Limited was incorporated in 1991 and listed on the Australian Securities Exchange (ASX) in 1994.

Today, CSL comprises businesses with longstanding, specialized expertise: CSL Behring, a global leader in rare and serious diseases; CSL Seqirus, one of the largest influenza vaccine providers in the world; CSL Plasma, the world's largest plasma collection company; and, most recently, CSL Vifor, a leader in iron deficiency and nephrology. Together, our combined and robust histories are delivering a healthier today and a better tomorrow for patients and people everywhere.